SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Marshall Woodworth will be appointed new Chief Financial Officer. Anders Murman will be promoted to Chief Technology Officer.
Marshall Woodworth will be appointed Chief Financial Officer of Aerocrine, AB, effective June 13, 2014. The CFO position will be based in Aerocrine’s US-office in Morrisville, North Carolina and will also have an office in Solna, Sweden. The leadership change is in alignment with Aerocrine’s strategic direction and increased focus on key markets such as US. Aerocrine will remain a Swedish Public Company.
Marshall Woodworth was formerly CFO of Furiex Pharmaceuticals, Inc., a US-based biotech company that is currently in the process of being acquired by Forest Laboratories. He has more than 25 years of experience with Initial Public Offerings (IPO), financial reporting, mergers and acquisitions, fundraising and corporate finance functions. As CFO, Marshall Woodworth will report to Aerocrine’s CEO, Scott Myers.
Aerocrine’s current CFO, Michael Colerus, will assist in the transition. Michael Colerus has served as CFO since 1999 and has been instrumental in establishing Aerocrine as a commercial stage company and during the transition from a startup to a publicly listed company as well as during subsequent fundraisings.
Aerocrine is also announcing management changes in Technical Operations. Anders Murman is promoted to CTO of Aerocrine, effective immediately. Anders Murman has extensive experience in software & product development within the medical technology field and is joining Aerocrine from RaySearch Laboratories AB.
Mats Carlson, Aerocrine’s current CTO, is shifting roles to lead Global Business Development, Alliance Management and Customer Service. Since joining Aerocrine in 1998, Mats Carlson has led product development and technical operations and is credited with leading many of the innovations that have formed the basis for Aerocrine’s products. Mats Carlson and Anders Murman will report to the CEO. Both will remain based in Sweden.
Aerocrine AB (STO:AERO-B) is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU). Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.
Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:55 am on June 12, 2014
This information was brought to you by Cision http://news.cision.com